Astrazeneca annual cash and equivalents
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Cash & Equivalents Growth & History (AZN)
Astrazeneca's cash and equivalents was $5.71B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.71B | $223.0M | +4.06% |
| 2024 | 2024-12-31 | $5.49B | −$352.0M | −6.03% |
| 2023 | 2023-12-31 | $5.84B | −$326.0M | −5.29% |
| 2022 | 2022-12-31 | $6.17B | −$163.0M | −2.58% |
| 2021 | 2021-12-31 | $6.33B | −$1.50B | −19.19% |
| 2020 | 2020-12-31 | $7.83B | $2.46B | +45.87% |
| 2019 | 2019-12-31 | $5.37B | $538.0M | +11.14% |
| 2018 | 2018-12-31 | $4.83B | $1.51B | +45.34% |
| 2017 | 2017-12-31 | $3.32B | −$1.69B | −33.76% |
| 2016 | 2016-12-31 | $5.02B | −$1.22B | −19.58% |
| 2015 | 2015-12-31 | $6.24B | — | — |
Astrazeneca quarterly cash and equivalents
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.89B | −$2.17B | −30.67% |
| Q1 2026 | 2026-03-31 | $7.56B | — | — |
| Q4 2025 | 2025-12-31 | $5.71B | $223.0M | +4.06% |
| Q3 2025 | 2025-09-30 | $8.14B | — | — |
| Q2 2025 | 2025-06-30 | $7.06B | $142.0M | +2.05% |
| Q4 2024 | 2024-12-31 | $5.49B | −$352.0M | −6.03% |
| Q2 2024 | 2024-06-30 | $6.92B | $1.25B | +22.10% |
| Q4 2023 | 2023-12-31 | $5.84B | −$326.0M | −5.29% |
| Q2 2023 | 2023-06-30 | $5.66B | $847.0M | +17.58% |
| Q4 2022 | 2022-12-31 | $6.17B | −$163.0M | −2.58% |
| Q2 2022 | 2022-06-30 | $4.82B | −$10.75B | −69.06% |
| Q4 2021 | 2021-12-31 | $6.33B | −$1.50B | −19.19% |
| Q2 2021 | 2021-06-30 | $15.57B | $9.89B | +174.41% |
| Q4 2020 | 2020-12-31 | $7.83B | $2.46B | +45.87% |
| Q2 2020 | 2020-06-30 | $5.67B | $245.0M | +4.51% |
| Q4 2019 | 2019-12-31 | $5.37B | $538.0M | +11.14% |
| Q2 2019 | 2019-06-30 | $5.43B | $2.45B | +82.27% |
| Q4 2018 | 2018-12-31 | $4.83B | $1.51B | +45.34% |
| Q2 2018 | 2018-06-30 | $2.98B | — | — |
| Q4 2017 | 2017-12-31 | $3.32B | — | — |
Astrazeneca cash and equivalents trends
Over the last five fiscal years, Astrazeneca's cash and equivalents decreased from $7.83B to $5.71B, a change of −$2.12B. The latest reported quarter, Q2 2026, shows $4.89B.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...